Burzynski: The Cancer Cure Cover-Up

In the compelling follow-up to the internationally award-winning documentary, "Burzynski: the Movie,", Part II explores the current status of Antineoplastons' clinical testing sanctioned by the United States Food & Drug Administration - and features a modern story of the struggling journeys of cancer patients being treated today at the Burzynski Clinic in Houston, Texas. Since the mapping of the Cancer Genome, Burzynski has pioneered an expansion of his therapy, which he calls, "Personalized Gene-Targeted Cancer Therapy", where each patient's Genomic Cancer Atlas is mapped and a treatment regimen is personally tailored for each individual patient - vs. the conveyor belt, "one-size-fits-all" approach that current oncology adheres to.

Andorra, a tiny, independent country situated between France and Spain in the Pyrenees mountains with a total population of 80,000 people, found itself at the center of one of the most convoluted and outrageous bank robberies in modern history.

Michael Moore comes home to the issue he's been examining throughout his career: the disastrous impact of corporate dominance on the everyday lives of Americans (and by default, the rest of the world).

A new documentary exploring Fetal Stem Cell injections for a variety of neurological and immunological ailments.

The story of a young science-writer at Memorial Sloan-Kettering Cancer Center, who risked everything by blowing the whistle on a massive cover-up involving a promising cancer therapy.

Burzynski, the Movie is the story of a medical doctor and Ph.D biochemist named Dr. Stanislaw Burzynski who won the largest, and possibly the most convoluted and intriguing legal battle against the Food & Drug Administration in American history. His victorious battles with the United States government were centered around Dr. Burzynski's gene-targeted cancer medicines he discovered in the 1970's called Antineoplastons, which have currently completed Phase II FDA-supervised clinical trials in 2009 and could begin the final phase of FDA testing in 2011–barring the ability to raise the required $300 million to fund the final phase of FDA clinical trials.